David Kirn, 4D Molecular Therapeutics CEO

Eye­ing a hot IPO mar­ket, 4DMT tops up its cash re­serves and preps a leap in­to the clin­ic with be­spoke gene ther­a­py vec­tors

It took 4D Mol­e­c­u­lar Ther­a­peu­tics 7 years to build its gene ther­a­py vec­tor plat­form, line up a mar­quee in­dus­try deal and prep a string of INDs. And now it has the mon­ey to fund the next big stage as the team plans a near-term launch of their first clin­i­cal stud­ies to test its cus­tom-built gene ther­a­pies in hu­mans.

The 80-per­son 4DMT team led by CEO David Kirn put out word Tues­day morn­ing that they have land­ed a $75 mil­lion C round to keep the work on track.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.